Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

A recurrent and transesophageal echocardiography-associated outbreak of extended-spectrum β-lactamase-producing Enterobacter cloacae complex in cardiac surgery patients.

Van Maerken T, De Brabandere E, Noël A, Coorevits L, De Waegemaeker P, Ablorh R, Bouchez S, Herck I, Peperstraete H, Bogaerts P, Verhasselt B, Glupczynski Y, Boelens J, Leroux-Roels I.

Antimicrob Resist Infect Control. 2019 Sep 18;8:152. doi: 10.1186/s13756-019-0605-4. eCollection 2019.

2.

Cost-effective and robust genotyping using double-mismatch allele-specific quantitative PCR.

Lefever S, Rihani A, Van der Meulen J, Pattyn F, Van Maerken T, Van Dorpe J, Hellemans J, Vandesompele J.

Sci Rep. 2019 Feb 15;9(1):2150. doi: 10.1038/s41598-019-38581-z.

3.

Nosocomial outbreak of extended-spectrum β-lactamase-producing Enterobacter cloacae among cardiothoracic surgical patients: causes and consequences.

Noël A, Vastrade C, Dupont S, de Barsy M, Huang TD, Van Maerken T, Leroux-Roels I, Delaere B, Melly L, Rondelet B, Dransart C, Dincq AS, Michaux I, Bogaerts P, Glupczynski Y.

J Hosp Infect. 2019 May;102(1):54-60. doi: 10.1016/j.jhin.2019.01.001. Epub 2019 Jan 7.

PMID:
30630000
4.

ALK positively regulates MYCN activity through repression of HBP1 expression.

Claeys S, Denecker G, Durinck K, Decaesteker B, Mus LM, Loontiens S, Vanhauwaert S, Althoff K, Wigerup C, Bexell D, Dolman E, Henrich KO, Wehrmann L, Westerhout EM, Demoulin JB, Kumps C, Van Maerken T, Laureys G, Van Neste C, De Wilde B, De Wever O, Westermann F, Versteeg R, Molenaar JJ, Påhlman S, Schulte JH, De Preter K, Speleman F.

Oncogene. 2019 Apr;38(15):2690-2705. doi: 10.1038/s41388-018-0595-3. Epub 2018 Dec 11.

PMID:
30538293
5.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.

Zeka F, Decock A, Van Goethem A, Vanderheyden K, Demuynck F, Lammens T, Helsmoortel HH, Vermeulen J, Noguera R, Berbegall AP, Combaret V, Schleiermacher G, Laureys G, Schramm A, Schulte JH, Rahmann S, Bienertová-Vašků J, Mazánek P, Jeison M, Ash S, Hogarty MD, Moreno-Smith M, Barbieri E, Shohet J, Berthold F, Van Maerken T, Speleman F, Fischer M, De Preter K, Mestdagh P, Vandesompele J.

JCI Insight. 2018 Dec 6;3(23). pii: 97021. doi: 10.1172/jci.insight.97021.

6.

Performance of the preanalytical check module of the Stago STA R Max2 mechanical endpoint detection analyzer for assessing the impact of hemolysis, lipemia, and icterus on aPTT and PT.

Florin L, Oyaert M, Van Maerken T, Devreese KMJ.

Int J Lab Hematol. 2018 Dec;40(6):e109-e112. doi: 10.1111/ijlh.12871. Epub 2018 Jun 13. No abstract available.

PMID:
29900685
7.

Clinical burden of hepatitis E virus infection in a tertiary care center in Flanders, Belgium.

Cattoir L, Van Hoecke F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, Geerts A, Verhelst X, Colle I, Hutse V, Suin V, Wautier M, Van Gucht S, Van Vlierberghe H, Padalko E.

J Clin Virol. 2018 Jun;103:8-11. doi: 10.1016/j.jcv.2018.03.004. Epub 2018 Mar 19.

PMID:
29602096
8.

Analytical and pre-analytical performance characteristics of a novel cartridge-type blood gas analyzer for point-of-care and laboratory testing.

Oyaert M, Van Maerken T, Bridts S, Van Loon S, Laverge H, Stove V.

Clin Biochem. 2018 Mar;53:116-126. doi: 10.1016/j.clinbiochem.2018.01.007. Epub 2018 Jan 12.

PMID:
29339078
9.

Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11.

Baert A, Machackova E, Coene I, Cremin C, Turner K, Portigal-Todd C, Asrat MJ, Nuk J, Mindlin A, Young S, MacMillan A, Van Maerken T, Trbusek M, McKinnon W, Wood ME, Foulkes WD, Santamariña M, de la Hoya M, Foretova L, Poppe B, Vral A, Rosseel T, De Leeneer K, Vega A, Claes KBM.

Hum Mutat. 2018 Apr;39(4):515-526. doi: 10.1002/humu.23390. Epub 2018 Jan 22.

PMID:
29280214
10.

Meticulous plasma isolation is essential to avoid false low-level viraemia in Roche Cobas HIV-1 viral load assays.

Mortier V, Vancoillie L, Dauwe K, Staelens D, Demecheleer E, Schauvliege M, Dinakis S, Van Maerken T, Dessilly G, Ruelle J, Verhofstede C.

Antivir Ther. 2018;23(3):277-281. doi: 10.3851/IMP3203.

PMID:
29063859
11.

MicroRNA Expression Analysis Using Small RNA Sequencing Discovery and RT-qPCR-Based Validation.

Van Goethem A, Mestdagh P, Van Maerken T, Vandesompele J.

Methods Mol Biol. 2017;1654:197-208. doi: 10.1007/978-1-4939-7231-9_13.

PMID:
28986791
12.

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma.

Van Goethem A, Yigit N, Moreno-Smith M, Vasudevan SA, Barbieri E, Speleman F, Shohet J, Vandesompele J, Van Maerken T.

Oncotarget. 2017 Jul 4;8(34):57047-57057. doi: 10.18632/oncotarget.18982. eCollection 2017 Aug 22.

13.

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD.

Expert Opin Drug Discov. 2017 Aug;12(8):801-811. doi: 10.1080/17460441.2017.1340269. Epub 2017 Jun 26. Review.

PMID:
28604107
14.

Hepatitis E virus serology and PCR: does the methodology matter?

Cattoir L, Van Hoecke F, Van Maerken T, Nys E, Ryckaert I, De Boulle M, Geerts A, Verhelst X, Colle I, Hutse V, Suin V, Wautier M, Van Gucht S, Van Vlierberghe H, Padalko E.

Arch Virol. 2017 Sep;162(9):2625-2632. doi: 10.1007/s00705-017-3395-0. Epub 2017 May 18.

PMID:
28523520
15.

A negative lactate dehydrogenase activity corrected after sample neuraminidase treatment.

Oyaert M, Van Maerken T, Bauwens E, Stove V, Delanghe J.

Clin Chim Acta. 2017 May;468:209-210. doi: 10.1016/j.cca.2017.03.011. Epub 2017 Mar 12. No abstract available.

PMID:
28300541
16.

Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay.

Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.

Oncol Rep. 2017 Mar;37(3):1379-1386. doi: 10.3892/or.2017.5407. Epub 2017 Jan 25.

17.

Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis.

Küsters-Vandevelde HV, Kruse V, Van Maerken T, Boterberg T, Pfundt R, Creytens D, Van den Broecke C, Machielsen TC, Koelsche C, von Deimling A, Küsters B, Groenen PJ, Wesseling P, Blokx WA.

Exp Mol Pathol. 2017 Feb;102(1):25-31. doi: 10.1016/j.yexmp.2016.12.006. Epub 2016 Dec 11.

PMID:
27974237
18.

Depletion of tRNA-halves enables effective small RNA sequencing of low-input murine serum samples.

Van Goethem A, Yigit N, Everaert C, Moreno-Smith M, Mus LM, Barbieri E, Speleman F, Mestdagh P, Shohet J, Van Maerken T, Vandesompele J.

Sci Rep. 2016 Nov 30;6:37876. doi: 10.1038/srep37876.

19.

Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation.

Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Storm K, van den Ende J, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A.

Breast Cancer Res. 2016 May 17;18(1):52. doi: 10.1186/s13058-016-0709-1.

20.

An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.

Madorsky-Feldman D, Sklair-Levy M, Perri T, Laitman Y, Paluch-Shimon S, Schmutzler R, Rhiem K, Lester J, Karlan BY, Singer CF, Van Maerken T, Claes K, Brunet J, Izquierdo A, Teulé A, Lee JW, Kim SW, Arun B, Jakubowska A, Lubinski J, Tucker K, Poplawski NK, Varesco L, Bonelli LA, Buys SS, Mitchell G, Tischkowitz M, Gerdes AM, Seynaeve C, Robson M, Kwong A, Tung N, Tessa N, Domchek SM, Godwin AK, Rantala J, Arver B, Friedman E.

Breast Cancer Res Treat. 2016 Jun;157(2):319-327. doi: 10.1007/s10549-016-3805-0. Epub 2016 Apr 27.

21.

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.

Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, Mitchell G, James P, Thull DL, Zorn KK, Carter NJ, Nathanson KL, Domchek SM, Rebbeck TR, Ramus SJ, Nussbaum RL, Olopade OI, Rantala J, Yoon SY, Caligo MA, Spugnesi L, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Toland AE, Senter L, Andrulis IL, Glendon G, Hulick PJ, Imyanitov EN, Greene MH, Mai PL, Singer CF, Rappaport-Fuerhauser C, Kramer G, Vijai J, Offit K, Robson M, Lincoln A, Jacobs L, Machackova E, Foretova L, Navratilova M, Vasickova P, Couch FJ, Hallberg E, Ruddy KJ, Sharma P, Kim SW; kConFab Investigators, Teixeira MR, Pinto P, Montagna M, Matricardi L, Arason A, Johannsson OT, Barkardottir RB, Jakubowska A, Lubinski J, Izquierdo A, Pujana MA, Balmaña J, Diez O, Ivady G, Papp J, Olah E, Kwong A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Nevanlinna H, Aittomäki K, Perez Segura P, Caldes T, Van Maerken T, Poppe B, Claes KB, Isaacs C, Elan C, Lasset C, Stoppa-Lyonnet D, Barjhoux L, Belotti M, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Kast K, Arnold N, Varon-Mateeva R, Wand D, Godwin AK, Evans DG, Frost D, Perkins J, Adlard J, Izatt L, Platte R, Eeles R, Ellis S; EMBRACE, Hamann U, Garber J, Fostira F, Fountzilas G, Pasini B, Giannini G, Rizzolo P, Russo A, Cortesi L, Papi L, Varesco L, Palli D, Zanna I, Savarese A, Radice P, Manoukian S, Peissel B, Barile M, Bonanni B, Viel A, Pensotti V, Tommasi S, Peterlongo P, Weitzel JN, Osorio A, Benitez J, McGuffog L, Healey S, Gerdes AM, Ejlertsen B, Hansen TV, Steele L, Ding YC, Tung N, Janavicius R, Goldgar DE, Buys SS, Daly MB, Bane A, Terry MB, John EM, Southey M, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L.

Breast Cancer Res. 2016 Feb 9;18(1):15. doi: 10.1186/s13058-016-0671-y.

22.

BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.

Francies FZ, Wainstein T, De Leeneer K, Cairns A, Murdoch M, Nietz S, Cubasch H, Poppe B, Van Maerken T, Crombez B, Coene I, Kerr R, Slabbert JP, Vral A, Krause A, Baeyens A, Claes KB.

BMC Cancer. 2015 Nov 17;15:912. doi: 10.1186/s12885-015-1913-6.

23.

Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma.

Rihani A, Vandesompele J, Speleman F, Van Maerken T.

Cancer Cell Int. 2015 Jul 30;15:76. doi: 10.1186/s12935-015-0224-y. eCollection 2015.

24.

Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.

Schwermer M, Lee S, Köster J, van Maerken T, Stephan H, Eggert A, Morik K, Schulte JH, Schramm A.

Oncotarget. 2015 Jun 20;6(17):15425-35.

25.

Identification of miRNAs contributing to neuroblastoma chemoresistance.

Ayers D, Mestdagh P, Van Maerken T, Vandesompele J.

Comput Struct Biotechnol J. 2015 Apr 29;13:307-19. doi: 10.1016/j.csbj.2015.04.003. eCollection 2015.

26.

Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.

Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Ramón y Cajal T, Nevanlinna H, Aittomäki K, Arun BK, Toland AE, Karlan BY, Walsh C, Lester J, Greene MH, Mai PL, Nussbaum RL, Andrulis IL, Domchek SM, Nathanson KL, Rebbeck TR, Barkardottir RB, Jakubowska A, Lubinski J, Durda K, Jaworska-Bieniek K, Claes K, Van Maerken T, Díez O, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, de la Hoya M, Caldés T, Dunning AM, Oliver C, Fineberg E, Cook M, Peock S, McCann E, Murray A, Jacobs C, Pichert G, Lalloo F, Chu C, Dorkins H, Paterson J, Ong KR, Teixeira MR; Teixeira, Hogervorst FB, van der Hout AH, Seynaeve C, van der Luijt RB, Ligtenberg MJ, Devilee P, Wijnen JT, Rookus MA, Meijers-Heijboer HE, Blok MJ, van den Ouweland AM, Aalfs CM, Rodriguez GC, Phillips KA, Piedmonte M, Nerenstone SR, Bae-Jump VL, O'Malley DM, Ratner ES, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Bojesen A, Pedersen IS, Sunde L, Jensen UB, Thomassen M, Kruse TA, Foretova L, Peterlongo P, Bernard L, Peissel B, Scuvera G, Manoukian S, Radice P, Ottini L, Montagna M, Agata S, Maugard C, Simard J, Soucy P, Berger A, Fink-Retter A, Singer CF, Rappaport C, Geschwantler-Kaulich D, Tea MK, Pfeiler G; BCFR, John EM, Miron A, Neuhausen SL, Terry MB, Chung WK, Daly MB, Goldgar DE, Janavicius R, Dorfling CM, van Rensburg EJ, Fostira F, Konstantopoulou I, Garber J, Godwin AK, Olah E, Narod SA, Rennert G, Paluch SS, Laitman Y, Friedman E; SWE-BRCA, Liljegren A, Rantala J, Stenmark-Askmalm M, Loman N, Imyanitov EN, Hamann U; kConFab Investigators, Spurdle AB, Healey S, Weitzel JN, Herzog J, Margileth D, Gorrini C, Esteller M, Gómez A, Sayols S, Vidal E, Heyn H; GEMO, Stoppa-Lyonnet D, Léoné M, Barjhoux L, Fassy-Colcombet M, de Pauw A, Lasset C, Ferrer SF, Castera L, Berthet P, Cornelis F, Bignon YJ, Damiola F, Mazoyer S, Sinilnikova OM, Maxwell CA, Vijai J, Robson M, Kauff N, Corines MJ, Villano D, Cunningham J, Lee A, Lindor N, Lázaro C, Easton DF, Offit K, Chenevix-Trench G, Couch FJ, Antoniou AC, Pujana MA.

PLoS One. 2015 Apr 1;10(4):e0120020. doi: 10.1371/journal.pone.0120020. eCollection 2015.

27.

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.

Lambertz I, Kumps C, Claeys S, Lindner S, Beckers A, Janssens E, Carter DR, Cazes A, Cheung BB, De Mariano M, De Bondt A, De Brouwer S, Delattre O, Gibbons J, Janoueix-Lerosey I, Laureys G, Liang C, Marchall GM, Porcu M, Takita J, Trujillo DC, Van Den Wyngaert I, Van Roy N, Van Goethem A, Van Maerken T, Zabrocki P, Cools J, Schulte JH, Vialard J, Speleman F, De Preter K.

Clin Cancer Res. 2015 Jul 15;21(14):3327-39. doi: 10.1158/1078-0432.CCR-14-2024. Epub 2015 Mar 24.

28.

Genome wide expression profiling of p53 regulated miRNAs in neuroblastoma.

Rihani A, Van Goethem A, Ongenaert M, De Brouwer S, Volders PJ, Agarwal S, De Preter K, Mestdagh P, Shohet J, Speleman F, Vandesompele J, Van Maerken T.

Sci Rep. 2015 Mar 12;5:9027. doi: 10.1038/srep09027.

29.

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.

Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, Van Maerken T.

PLoS One. 2014 Dec 11;9(12):e114696. doi: 10.1371/journal.pone.0114696. eCollection 2014.

30.

Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.

Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gómez Garcia EB, Olopade OI, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Karlan BY, Orsulic S, Lester J, Chung WK, Miron A, Southey MC, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Ding YC, Neuhausen SL, Hansen TV, Gerdes AM, Ejlertsen B, Jønson L, Osorio A, Martínez-Bouzas C, Benitez J, Conway EE, Blazer KR, Weitzel JN, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Barile M, Ficarazzi F, Mariette F, Fortuzzi S, Viel A, Giannini G, Papi L, Martayan A, Tibiletti MG, Radice P, Vratimos A, Fostira F, Garber JE, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Davidson R, Hodgson SV, Ellis S, Cole T; EMBRACE, Godwin AK, Claes K, Van Maerken T, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Wappenschmidt B, Wang-Gohrke S, Bressac-de Paillerets B, Buecher B, Delnatte C, Houdayer C, Stoppa-Lyonnet D, Damiola F, Coupier I, Barjhoux L, Venat-Bouvet L, Golmard L, Boutry-Kryza N, Sinilnikova OM, Caron O, Pujol P, Mazoyer S, Belotti M; GEMO Study Collaborators, Piedmonte M, Friedlander ML, Rodriguez GC, Copeland LJ, de la Hoya M, Segura PP, Nevanlinna H, Aittomäki K, van Os TA, Meijers-Heijboer HE, van der Hout AH, Vreeswijk MP, Hoogerbrugge N, Ausems MG, van Doorn HC, Collée JM; HEBON, Olah E, Diez O, Blanco I, Lazaro C, Brunet J, Feliubadalo L, Cybulski C, Gronwald J, Durda K, Jaworska-Bieniek K, Sukiennicki G, Arason A, Chiquette J, Teixeira MR, Olswold C, Couch FJ, Lindor NM, Wang X, Szabo CI, Offit K, Corines M, Jacobs L, Robson ME, Zhang L, Joseph V, Berger A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Glendon G, Tchatchou S, Andrulis IL, Toland AE, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Laitman Y, Rantala J, von Wachenfeldt A, Ehrencrona H, Askmalm MS, Borg Å, Kuchenbaecker KB, McGuffog L, Barrowdale D, Healey S, Lee A, Pharoah PD, Chenevix-Trench G; KConFab Investigators, Antoniou AC, Friedman E.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):308-16. doi: 10.1158/1055-9965.EPI-14-0532. Epub 2014 Oct 21.

31.

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.

Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J.

Pediatr Blood Cancer. 2014 Oct;61(10):1867-70. doi: 10.1002/pbc.24927. Epub 2014 Jan 4.

PMID:
24391119
32.

MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance.

Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson AD, Van Maerken T.

Curr Drug Targets. 2014 Jan;15(1):114-23. Review.

PMID:
24387312
33.

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.

Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, Radice P, Ramus SJ, Domchek SM, Nathanson KL, Lee A, Healey S, Nussbaum RL, Rebbeck TR, Arun BK, James P, Karlan BY, Lester J, Cass I; Breast Cancer Family Registry, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, v O Hansen T, Ejlertsen B, Gerdes AM, Nielsen FC, Dennis J, Cunningham J, Hart S, Slager S, Osorio A, Benitez J, Duran M, Weitzel JN, Tafur I, Hander M, Peterlongo P, Manoukian S, Peissel B, Roversi G, Scuvera G, Bonanni B, Mariani P, Volorio S, Dolcetti R, Varesco L, Papi L, Tibiletti MG, Giannini G, Fostira F, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE Study, Douglas F, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Ellis S, Godwin AK, Rhiem K, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Steinemann D, Bogdanova-Markov N, Kast K, Varon-Mateeva R, Wang-Gohrke S, Gehrig A, Markiefka B, Buecher B, Lefol C, Stoppa-Lyonnet D, Rouleau E, Prieur F, Damiola F; GEMO Study Collaborators, Barjhoux L, Faivre L, Longy M, Sevenet N, Sinilnikova OM, Mazoyer S, Bonadona V, Caux-Moncoutier V, Isaacs C, Van Maerken T, Claes K, Piedmonte M, Andrews L, Hays J, Rodriguez GC, Caldes T, de la Hoya M, Khan S, Hogervorst FB, Aalfs CM, de Lange JL, Meijers-Heijboer HE, van der Hout AH, Wijnen JT, van Roozendaal KE, Mensenkamp AR, van den Ouweland AM, van Deurzen CH, van der Luijt RB; HEBON, Olah E, Diez O, Lazaro C, Blanco I, Teulé A, Menendez M, Jakubowska A, Lubinski J, Cybulski C, Gronwald J, Jaworska-Bieniek K, Durda K, Arason A, Maugard C, Soucy P, Montagna M, Agata S, Teixeira MR; KConFab Investigators, Olswold C, Lindor N, Pankratz VS, Hallberg E, Wang X, Szabo CI, Vijai J, Jacobs L, Corines M, Lincoln A, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Mai PL, Greene MH, Rennert G, Imyanitov EN, Glendon G, Toland AE, Bojesen A, Pedersen IS, Jensen UB, Caligo MA, Friedman E, Berger R, Laitman Y, Rantala J, Arver B, Loman N, Borg A, Ehrencrona H, Olopade OI, Simard J, Easton DF, Chenevix-Trench G, Offit K, Couch FJ, Antoniou AC; CIMBA.

Breast Cancer Res. 2014 Dec 31;16(6):3416. doi: 10.1186/s13058-014-0492-9.

34.

Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer.

Van Maerken T, Rihani A, Van Goethem A, De Paepe A, Speleman F, Vandesompele J.

Cancer Lett. 2014 Mar 28;344(2):157-65. doi: 10.1016/j.canlet.2013.11.002. Epub 2013 Nov 18. Review.

PMID:
24262662
35.

Effective Alu repeat based RT-Qpcr normalization in cancer cell perturbation experiments.

Rihani A, Van Maerken T, Pattyn F, Van Peer G, Beckers A, De Brouwer S, Kumps C, Mets E, Van der Meulen J, Rondou P, Leonelli C, Mestdagh P, Speleman F, Vandesompele J.

PLoS One. 2013 Aug 14;8(8):e71776. doi: 10.1371/journal.pone.0071776. eCollection 2013.

36.

Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.

Kumps C, Fieuw A, Mestdagh P, Menten B, Lefever S, Pattyn F, De Brouwer S, Sante T, Schulte JH, Schramm A, Van Roy N, Van Maerken T, Noguera R, Combaret V, Devalck C, Westermann F, Laureys G, Eggert A, Vandesompele J, De Preter K, Speleman F.

PLoS One. 2013;8(1):e52321. doi: 10.1371/journal.pone.0052321. Epub 2013 Jan 4.

37.

Hepatitis E seroprevalence in east and west Flanders, Belgium.

Van Hoecke F, Van Maerken T, De Boulle M, Geerts A, Vlierberghe V, Colle I, Padalko HE.

Acta Gastroenterol Belg. 2012 Sep;75(3):322-4.

PMID:
23082702
38.

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J.

Genome Biol. 2012 Oct 3;13(10):R95. doi: 10.1186/gb-2012-13-10-r95.

39.

Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer.

Ferdinande L, Decaestecker C, Verset L, Mathieu A, Moles Lopez X, Negulescu AM, Van Maerken T, Salmon I, Cuvelier CA, Demetter P.

Br J Cancer. 2012 Jan 3;106(1):141-7. doi: 10.1038/bjc.2011.513. Epub 2011 Nov 22.

40.

EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells.

De Weer A, Van der Meulen J, Rondou P, Taghon T, Konrad TA, De Preter K, Mestdagh P, Van Maerken T, Van Roy N, Jeison M, Yaniv I, Cauwelier B, Noens L, Poirel HA, Vandenberghe P, Lambert F, De Paepe A, Sánchez MG, Odero M, Verhasselt B, Philippé J, Vandesompele J, Wieser R, Dastugue N, Van Vlierberghe P, Poppe B, Speleman F.

Br J Haematol. 2011 Aug;154(3):337-48. doi: 10.1111/j.1365-2141.2011.08737.x. Epub 2011 May 14.

PMID:
21569010
41.

Functional analysis of the p53 pathway in neuroblastoma cells using the small-molecule MDM2 antagonist nutlin-3.

Van Maerken T, Rihani A, Dreidax D, De Clercq S, Yigit N, Marine JC, Westermann F, De Paepe A, Vandesompele J, Speleman F.

Mol Cancer Ther. 2011 Jun;10(6):983-93. doi: 10.1158/1535-7163.MCT-10-1090. Epub 2011 Apr 1.

42.

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.

De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F.

Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18.

43.

An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours.

Mestdagh P, Fredlund E, Pattyn F, Rihani A, Van Maerken T, Vermeulen J, Kumps C, Menten B, De Preter K, Schramm A, Schulte J, Noguera R, Schleiermacher G, Janoueix-Lerosey I, Laureys G, Powel R, Nittner D, Marine JC, Ringnér M, Speleman F, Vandesompele J.

Oncogene. 2010 Jun 17;29(24):3583-92. doi: 10.1038/onc.2010.106. Epub 2010 Apr 12.

PMID:
20383195
44.

A rapid and simple assay to determine pegylated erythropoietin in human serum.

Van Maerken T, Dhondt A, Delanghe JR.

J Appl Physiol (1985). 2010 Apr;108(4):800-3. doi: 10.1152/japplphysiol.01102.2009. Epub 2010 Jan 21.

45.

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.

J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74. doi: 10.1093/jnci/djp355. Epub 2009 Nov 10.

PMID:
19903807
46.

Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.

Van Maerken T, Vandesompele J, Rihani A, De Paepe A, Speleman F.

Cell Death Differ. 2009 Dec;16(12):1563-72. doi: 10.1038/cdd.2009.138. Epub 2009 Sep 25. Review.

47.

The emerging molecular pathogenesis of neuroblastoma: implications for improved risk assessment and targeted therapy.

Van Roy N, De Preter K, Hoebeeck J, Van Maerken T, Pattyn F, Mestdagh P, Vermeulen J, Vandesompele J, Speleman F.

Genome Med. 2009 Jul 27;1(7):74. doi: 10.1186/gm74.

48.

Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma.

Lee SG, Jeon HY, Su ZZ, Richards JE, Vozhilla N, Sarkar D, Van Maerken T, Fisher PB.

Oncogene. 2009 Jul 2;28(26):2476-84. doi: 10.1038/onc.2009.93. Epub 2009 May 18.

PMID:
19448665
49.

Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds.

De Preter K, De Brouwer S, Van Maerken T, Pattyn F, Schramm A, Eggert A, Vandesompele J, Speleman F.

Clin Cancer Res. 2009 Jun 1;15(11):3690-6. doi: 10.1158/1078-0432.CCR-08-2699. Epub 2009 May 12.

50.

Adenovirus-mediated hPNPase(old-35) gene transfer as a therapeutic strategy for neuroblastoma.

Van Maerken T, Sarkar D, Speleman F, Dent P, Weiss WA, Fisher PB.

J Cell Physiol. 2009 Jun;219(3):707-15. doi: 10.1002/jcp.21719.

Supplemental Content

Loading ...
Support Center